# Obinutuzumab in Adult Rituximab-Dependent Nephrotic Syndrome

> **NCT07233330** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Mario Negri Institute for Pharmacological Research** · enrollment: 10 (estimated)

## Conditions studied

- Nephrotic Syndrome，Idiopathic

## Interventions

- **DRUG:** Obinutuzumab

## Key facts

- **NCT ID:** NCT07233330
- **Lead sponsor:** Mario Negri Institute for Pharmacological Research
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-02
- **Primary completion:** 2029-03
- **Final completion:** 2029-03
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2026-01-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07233330

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07233330, "Obinutuzumab in Adult Rituximab-Dependent Nephrotic Syndrome". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07233330. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*